Initial study of transdermal oxybutynin for treating hyperhidrosis

Abstract

Oral oxybutynin for treating hyperhidrosis is effective and safe. Its side-effects are mild but frequent so we consider whether transdermal oxybutynin (considered to have a better side-effect profile) could be an alternative for treating hyperhidrosis. During 2015, a prospective study was conducted. Epidemiological variables, effectiveness (using the Hyperhidrosis Disease Severity Scale) and tolerance to transdermal oxybutynin were compiled concerning two different groups (patients previously treated or untreated with oral oxybutynin), at baseline, and at 3 and 12 months. Seven previously treated and six previously untreated patients were included. Five patients in the first group discontinued the treatment within 3 months. Of the two remaining patients, one reported ineffectiveness and the other obtained an excellent response but discontinued due to local irritation. Among the untreated patients, two showed no response and four experienced improvement (three with "partial response" and one with "excellent response"). All patients discontinued treatment within 12 months. No major adverse effects were observed. The absence of active metabolites after transdermal oxybutynin could result in less effectiveness than oral oxybutynin, although it is usually well tolerated. In conclusion, transdermal oxybutynin could have low effectiveness for the treatment of hyperhidrosis in patients following intolerance to oral oxybutynin but could provide good results in patients who have never tried systemic drugs.

<p>Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions</p>

“…However, transdermal oxybutynin showed effectiveness only in patients who had not received systemic drugs, but this response was of short duration (<12 months). 84 The contribution of this approach, although currently of limited value, is not yet possible to interpret.…”

Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10%

“…Both the OC gel 3% by Nguyen et al 6 and the OC gel 10% by Artzi et al 7 case series reported promising efficacy and adequate safety. In the Millan-Cayetano et al 8 assessment of the OC patches, only 15 out of 25 patients reported significant efficacy and in the Berg on-Send ın study, 9…”

“…Assessment in focal hyperhidrosis is controversial with a significant number of patients discontinuing treatment due to lack of efficacy or adverse effects. [6][7][8][9] Our objective was to evaluate the efficacy of a different formulation, a cream of oxybutynin chloride 10% prepared as a galenic formulation.…”

“…[5][6][7] Tildrakizumab is a high-affinity, humanized, immunoglobulin G1j, anti-interleukin-23p19 monoclonal antibody approved to treat plaque psoriasis. [8][9][10] The 64-week phase 3 reSURFACE 1 (NCT01722331) study in adult patients with moderate-to-severe plaque psoriasis required tildrakizumab-treated patients who achieved ≥75% improvement from baseline Psoriasis Area and Severity Index score (PASI 75; responders) at Week 28 to be rerandomized to either continued tildrakizumab treatment or withdrawal (placebo) with retreatment with their initial dose of tildrakizumab upon relapse (loss of 50% of maximum PASI benefit from baseline). 8 This post hoc analysis evaluated residual disease in tildrakizumab 100 mg responders in reSURFACE 1 who were continuously treated and those rerandomized to treatment interruption and retreatment upon relapse.…”

Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages

“…[132] Use of transdermal patches led to mixed results. [145,146] Hence, studies were performed to investigate the topical application of oxybutynin for the treatment of primary focal hyperhidrosis in adults, adolescents and young adults. In adults with primary focal hyperhidrosis, a 10% oxybutynin gel appeared to be an effective and well-tolerated treatment in an RCT (NCT02973659).…”